Ivantis Completes PMA Submission for Hydrus Microstent

November 3, 2017: By Jon Swedien
Ivantis Hydrus

Ivantis Hydrus

Ivantis has submitted to the US FDA its final premarket approval (PMA) module for the Hydrus Microstent as a treatment for open-angle glaucoma, the Irvine, California, company announced Oct. 31.

The Hydrus is a minimally invasive glaucoma surgery (MIGS) device designed to reduce intraocular pressure (IOP). Roughly the size of an eyelash, the device opens a bypass through the trabecular meshwork and then dilates and scaffolds Schlemm’s canal to enhance outflow.

The submission is based on the HORIZON pivotal trial, a 556 patient, prospective, randomized trial conducted at 38 centers in nine countries. Study subjects with mild to moderate primary open-angle glaucoma were randomized to receive cataract surgery alone or cataract surgery plus the Hydrus. Subjects were followed for two years. The HORIZON Study is the largest MIGS randomized controlled trial completed to date and the first pivotal trial to span the globe, Ivantis said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023